3 results
Approved WMOPending
Primary:To evaluate the clinical activity of GSK525762 in NUT Midline Carcinoma and other solid tumors.Secondary:Effect of treatment with GSK525762 on tumor growth and survival. Pharmacokinetics of GSK525762. Safety.
Approved WMOCompleted
ยท To evaluate the effect of zibotentan anddapagliflozin in combination and alone versusplacebo on UACR.
Approved WMORecruiting
The aim of this prospective proof-of-concept study is to increase the expression of the SSTR2 in NET patients with negative or low expression to levels amenable for somatostatin analogue treatment through the use of epigenetic drugs.